Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures

Elisa Carra, Federica Barbieri, Daniela Marubbi, Alessandra Pattarozzi, Roberto E. Favoni, Tullio Florio, Antonio Daga

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Glioblastomas are grade IV brain tumors characterized by high aggressiveness and invasiveness, giving patients a poor prognosis. We investigated the effects of the multi-kinase inhibitor sorafenib on six cultures isolated from human glioblastomas and maintained in tumor initiating cells-enriching conditions. These cell subpopulations are thought to be responsible for tumor recurrence and radio- and chemo-resistance, representing the perfect target for glioblastoma therapy. Sorafenib reduces proliferation of glioblastoma cultures, and this effect depends, at least in part, on the inhibition of PI3K/Akt and MAPK pathways, both involved in gliomagenesis. Sorafenib significantly induces apoptosis/cell death via downregulation of the survival factor Mcl-1. We provide evidence that sorafenib has a selective action on glioblastoma stem cells, causing enrichment of cultures in differentiated cells, downregulation of the expression of stemness markers required to maintain malignancy (nestin, Olig2 and Sox2) and reducing cell clonogenic ability in vitro and tumorigenic potential in vivo. The selectivity of sorafenib effects on glioblastoma stem cells is confirmed by the lower sensitivity of glioblastoma cultures after differentiation as compared with the undifferentiated counterpart. Since current GBM therapy enriches the tumor in cancer stem cells, the evidence of a selective action of sorafenib on these cells is therapeutically relevant, even if, so far, results from first phase II clinical trials did not demonstrate its efficacy.

Original languageEnglish
Pages (from-to)491-500
Number of pages10
JournalCell Cycle
Volume12
Issue number3
DOIs
Publication statusPublished - Feb 1 2013

Fingerprint

Neoplastic Stem Cells
Glioblastoma
Cell Culture Techniques
Stem Cells
Down-Regulation
Nestin
Neoplasms
Phase II Clinical Trials
sorafenib
Radio
Phosphatidylinositol 3-Kinases
Brain Neoplasms
Cell Death
Phosphotransferases
Apoptosis
Recurrence
Survival
Therapeutics

Keywords

  • Glioblastoma
  • Mcl-1
  • Sorafenib
  • Stemness
  • Therapy
  • Tumor initiating cells

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Developmental Biology

Cite this

Carra, E., Barbieri, F., Marubbi, D., Pattarozzi, A., Favoni, R. E., Florio, T., & Daga, A. (2013). Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cycle, 12(3), 491-500. https://doi.org/10.4161/cc.23372

Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. / Carra, Elisa; Barbieri, Federica; Marubbi, Daniela; Pattarozzi, Alessandra; Favoni, Roberto E.; Florio, Tullio; Daga, Antonio.

In: Cell Cycle, Vol. 12, No. 3, 01.02.2013, p. 491-500.

Research output: Contribution to journalArticle

Carra, E, Barbieri, F, Marubbi, D, Pattarozzi, A, Favoni, RE, Florio, T & Daga, A 2013, 'Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures', Cell Cycle, vol. 12, no. 3, pp. 491-500. https://doi.org/10.4161/cc.23372
Carra E, Barbieri F, Marubbi D, Pattarozzi A, Favoni RE, Florio T et al. Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cycle. 2013 Feb 1;12(3):491-500. https://doi.org/10.4161/cc.23372
Carra, Elisa ; Barbieri, Federica ; Marubbi, Daniela ; Pattarozzi, Alessandra ; Favoni, Roberto E. ; Florio, Tullio ; Daga, Antonio. / Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. In: Cell Cycle. 2013 ; Vol. 12, No. 3. pp. 491-500.
@article{0464ac330d2f41df9c19b0b9a72eb784,
title = "Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures",
abstract = "Glioblastomas are grade IV brain tumors characterized by high aggressiveness and invasiveness, giving patients a poor prognosis. We investigated the effects of the multi-kinase inhibitor sorafenib on six cultures isolated from human glioblastomas and maintained in tumor initiating cells-enriching conditions. These cell subpopulations are thought to be responsible for tumor recurrence and radio- and chemo-resistance, representing the perfect target for glioblastoma therapy. Sorafenib reduces proliferation of glioblastoma cultures, and this effect depends, at least in part, on the inhibition of PI3K/Akt and MAPK pathways, both involved in gliomagenesis. Sorafenib significantly induces apoptosis/cell death via downregulation of the survival factor Mcl-1. We provide evidence that sorafenib has a selective action on glioblastoma stem cells, causing enrichment of cultures in differentiated cells, downregulation of the expression of stemness markers required to maintain malignancy (nestin, Olig2 and Sox2) and reducing cell clonogenic ability in vitro and tumorigenic potential in vivo. The selectivity of sorafenib effects on glioblastoma stem cells is confirmed by the lower sensitivity of glioblastoma cultures after differentiation as compared with the undifferentiated counterpart. Since current GBM therapy enriches the tumor in cancer stem cells, the evidence of a selective action of sorafenib on these cells is therapeutically relevant, even if, so far, results from first phase II clinical trials did not demonstrate its efficacy.",
keywords = "Glioblastoma, Mcl-1, Sorafenib, Stemness, Therapy, Tumor initiating cells",
author = "Elisa Carra and Federica Barbieri and Daniela Marubbi and Alessandra Pattarozzi and Favoni, {Roberto E.} and Tullio Florio and Antonio Daga",
year = "2013",
month = "2",
day = "1",
doi = "10.4161/cc.23372",
language = "English",
volume = "12",
pages = "491--500",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures

AU - Carra, Elisa

AU - Barbieri, Federica

AU - Marubbi, Daniela

AU - Pattarozzi, Alessandra

AU - Favoni, Roberto E.

AU - Florio, Tullio

AU - Daga, Antonio

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Glioblastomas are grade IV brain tumors characterized by high aggressiveness and invasiveness, giving patients a poor prognosis. We investigated the effects of the multi-kinase inhibitor sorafenib on six cultures isolated from human glioblastomas and maintained in tumor initiating cells-enriching conditions. These cell subpopulations are thought to be responsible for tumor recurrence and radio- and chemo-resistance, representing the perfect target for glioblastoma therapy. Sorafenib reduces proliferation of glioblastoma cultures, and this effect depends, at least in part, on the inhibition of PI3K/Akt and MAPK pathways, both involved in gliomagenesis. Sorafenib significantly induces apoptosis/cell death via downregulation of the survival factor Mcl-1. We provide evidence that sorafenib has a selective action on glioblastoma stem cells, causing enrichment of cultures in differentiated cells, downregulation of the expression of stemness markers required to maintain malignancy (nestin, Olig2 and Sox2) and reducing cell clonogenic ability in vitro and tumorigenic potential in vivo. The selectivity of sorafenib effects on glioblastoma stem cells is confirmed by the lower sensitivity of glioblastoma cultures after differentiation as compared with the undifferentiated counterpart. Since current GBM therapy enriches the tumor in cancer stem cells, the evidence of a selective action of sorafenib on these cells is therapeutically relevant, even if, so far, results from first phase II clinical trials did not demonstrate its efficacy.

AB - Glioblastomas are grade IV brain tumors characterized by high aggressiveness and invasiveness, giving patients a poor prognosis. We investigated the effects of the multi-kinase inhibitor sorafenib on six cultures isolated from human glioblastomas and maintained in tumor initiating cells-enriching conditions. These cell subpopulations are thought to be responsible for tumor recurrence and radio- and chemo-resistance, representing the perfect target for glioblastoma therapy. Sorafenib reduces proliferation of glioblastoma cultures, and this effect depends, at least in part, on the inhibition of PI3K/Akt and MAPK pathways, both involved in gliomagenesis. Sorafenib significantly induces apoptosis/cell death via downregulation of the survival factor Mcl-1. We provide evidence that sorafenib has a selective action on glioblastoma stem cells, causing enrichment of cultures in differentiated cells, downregulation of the expression of stemness markers required to maintain malignancy (nestin, Olig2 and Sox2) and reducing cell clonogenic ability in vitro and tumorigenic potential in vivo. The selectivity of sorafenib effects on glioblastoma stem cells is confirmed by the lower sensitivity of glioblastoma cultures after differentiation as compared with the undifferentiated counterpart. Since current GBM therapy enriches the tumor in cancer stem cells, the evidence of a selective action of sorafenib on these cells is therapeutically relevant, even if, so far, results from first phase II clinical trials did not demonstrate its efficacy.

KW - Glioblastoma

KW - Mcl-1

KW - Sorafenib

KW - Stemness

KW - Therapy

KW - Tumor initiating cells

UR - http://www.scopus.com/inward/record.url?scp=84875522870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875522870&partnerID=8YFLogxK

U2 - 10.4161/cc.23372

DO - 10.4161/cc.23372

M3 - Article

C2 - 23324350

AN - SCOPUS:84875522870

VL - 12

SP - 491

EP - 500

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 3

ER -